Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9162427rdf:typepubmed:Citationlld:pubmed
pubmed-article:9162427lifeskim:mentionsumls-concept:C0019196lld:lifeskim
pubmed-article:9162427lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:9162427lifeskim:mentionsumls-concept:C0178795lld:lifeskim
pubmed-article:9162427lifeskim:mentionsumls-concept:C0021027lld:lifeskim
pubmed-article:9162427lifeskim:mentionsumls-concept:C1521797lld:lifeskim
pubmed-article:9162427lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:9162427lifeskim:mentionsumls-concept:C1708528lld:lifeskim
pubmed-article:9162427lifeskim:mentionsumls-concept:C2699007lld:lifeskim
pubmed-article:9162427pubmed:issue2lld:pubmed
pubmed-article:9162427pubmed:dateCreated1997-5-27lld:pubmed
pubmed-article:9162427pubmed:abstractTextVertical transmission of the HCV infection is asymptomatic, occurring in 0-25% of infants born to viremic mothers in Europe. Nowadays, the only preventive measure in to advise against breastfeeding. Favourable conditions for a seroprophylaxis trial in neonates at risk are the low viral charge and the absence of former replication or integration. Several impediments to a randomized-controlled trial should be considered: Epidemiological: paucity of recruitment; low risk of transmission; possible antenatal transmission in cases of high maternal viremia; risk for intrafamilial transmission. Methodological: complex randomization of the study groups (genotyping, quantitative PCR, activity of mothers' diseases, modes/durations of delivery and feeding). Ethical: a direct individual benefit is not clearly established; should viremic mothers be allowed to breast feed their babies in the absence of prophylaxis? the risk of the emergence of mutants or quasi-species of the transmitted hepatitis C virus in neonates; the origin and selection of seropositive plasma donors.lld:pubmed
pubmed-article:9162427pubmed:languagefrelld:pubmed
pubmed-article:9162427pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9162427pubmed:citationSubsetIMlld:pubmed
pubmed-article:9162427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9162427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9162427pubmed:statusMEDLINElld:pubmed
pubmed-article:9162427pubmed:issn1246-7820lld:pubmed
pubmed-article:9162427pubmed:authorpubmed-author:SouliéJ CJClld:pubmed
pubmed-article:9162427pubmed:issnTypePrintlld:pubmed
pubmed-article:9162427pubmed:volume4lld:pubmed
pubmed-article:9162427pubmed:ownerNLMlld:pubmed
pubmed-article:9162427pubmed:authorsCompleteYlld:pubmed
pubmed-article:9162427pubmed:pagination213-9lld:pubmed
pubmed-article:9162427pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:meshHeadingpubmed-meshheading:9162427-...lld:pubmed
pubmed-article:9162427pubmed:year1997lld:pubmed
pubmed-article:9162427pubmed:articleTitle[Rationale for a trial of prevention of perinatal transmission of hepatitis C via specific immunoglobulins].lld:pubmed
pubmed-article:9162427pubmed:affiliationCentre d'hémobiologie périnatale, Hôpital Jean-Verdier, Bondy.lld:pubmed
pubmed-article:9162427pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9162427pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:9162427pubmed:publicationTypeReviewlld:pubmed